文献速递艾滋病与性传播感染

抗逆转录病毒治疗降低HIV控制者的T细胞活化与免疫耗竭标志物

Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers.
PubMed 文献 · Clin Infect Dis · 2020-01-01

A5308是一项前瞻性开放标签研究,纳入35例未接受抗逆转录病毒治疗(ART)的HIV控制者,给予利匹韦林/恩曲他滨/富马酸替诺福韦二吡呋酯治疗。

要点

  • ART可进一步抑制HIV控制者的残留病毒血症。
  • ART显著降低CD8+ T细胞活化与免疫耗竭标志物。
  • ART对CD4+计数和HIV DNA无显著影响。

核心结论

  • 在HIV控制者中,ART降低T细胞活化并改善免疫耗竭标志物,支持该人群可能的临床获益。

研究设计与样本

  • A5308为前瞻性、开放标签研究,纳入35例未接受ART的HIV控制者(HIV RNA<500 copies/mL持续≥12个月)。
  • 干预为利匹韦林/恩曲他滨/富马酸替诺福韦二吡呋酯,主要结局为CD38+HLA-DR+ CD8+ T细胞百分比变化。

主要发现

  • ART前,残留病毒血症<0.6 HIV-1 RNA copies/mL者较可检测者CD4+计数更高、T细胞活化水平更低。
  • ART使用导致多个细胞免疫耗竭标志物下降,并带来自报生活质量的轻度但显著改善。
  • CD4+计数或HIV DNA无显著变化。

临床怎么用

  • 对于HIV控制者,可考虑启动ART以降低T细胞活化及免疫耗竭,并进一步抑制残留病毒血症。

局限性

  • 研究为开放标签、单臂设计,样本量较小(N=35)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Despite low plasma human immunodeficiency virus (HIV) RNA, HIV controllers have evidence of viral replication and elevated inflammation. We assessed the effect of antiretroviral therapy (ART) on HIV suppression, immune activation, and quality of life (QoL). METHODS: A5308 was a prospective, open-label study of rilpivirine/emtricitabine/tenofovir disoproxil fumarate in ART-naive HIV controllers (N = 35), defined as having HIV RNA <500 copies/mL for ≥12 months. The primary outcome measured change in %CD38+HLA-DR+ CD8+ T cells. Residual plasma viremia was measured using the integrase single-copy assay. QoL was measured using the EQ-5D questionnaire. Outcomes were evaluated using repeated measures general estimating equations models. RESULTS: Before ART, HIV controllers with undetectable residual viremia <0.6 HIV-1 RNA copies/mL had higher CD4+ counts and lower levels of T-cell activation than those with detectable residual viremia. ART use was effective in further increasing the proportion of individuals with undetectable residual viremia (pre-ART vs after 24-48 weeks of ART: 19% vs 94%, P < .001). Significant declines were observed in the %CD38+HLA-DR+CD8+ T cells at 24-48 (-4.0%, P = .001) and 72-96 (-7.2%, P < .001) weeks after ART initiation. ART use resulted in decreases of several cellular markers of immune exhaustion and in a modest but significant improvement in self-reported QoL. There were no significant changes in CD4+ counts or HIV DNA. CONCLUSIONS: ART in HIV controllers reduces T-cell activation and improves markers of immune exhaustion. These results support the possible clinical benefits of ART in this population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Li JZ, Segal FP, Bosch RJ, et al. Antiretroviral Therapy Reduces T-cell Activation and Immune Exhaustion Markers in Human Immunodeficiency Virus Controllers. Clin Infect Dis. 2020. PMID: 31131858. doi:10.1093/cid/ciz442

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。